Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells.
C J Heyser, R E Hampson, S A Deadwyler
Journal of Pharmacology and Experimental Therapeutics 1993 DOI: 10.1016/s0022-3565(25)10268-1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Rats (Sprague-Dawley), with hippocampal recordings from six animals |
| Interventions | Delta-9-tetrahydrocannabinol (delta-9-THC) cannabidiol vehicle |
| Dose | 0.75-2.0 mg/kg |
| Topics | Cannabis |
| Keywords | Hippocampus Animals Rats, sprague-dawley Behavior, animal Learning Memory Psychomotor performance Action potentials Dose-response relationship, drug Time factors Male Dronabinol |
| Key findings | Delta-9-THC (0.75-2.0 mg/kg) impaired DMTS performance in a delay- and dose-dependent manner, an effect reversible within 24 hours and not produced by vehicle or cannabidiol. The deficit was associated with a specific decrease in hippocampal complex spike cell discharge during the Sample phase of the task, which the authors suggest may explain short-term memory and cognitive deficits reported in humans after marijuana smoking. |
Abstract
The effects of delta-9-tetrahydrocannabinol (delta-9-THC) were studied during performance of a delayed match to sample (DMTS) task in rats. Correlated hippocampal cellular activity was also assessed in terms of the effects of cannabinoids on well characterized task specific changes in firing rate which occurred during various phases of a DMTS trial. Results show a surprising correlation between the delay and dose (0.75-2.0 mg/kg)-dependent behavioral deficit produced by delta-9-THC in this task and similar effects produced by damage to the hippocampus and related structures. However, unlike the effects of hippocampal lesions or neurotoxic damage, the effects of delta-9-THC were completely reversible within 24 hr of injection. Neither control injection of the vehicle nor equivalent concentrations of the nonpsychoactive cannabinoid, cannabidiol, produced alterations in DMTS performance levels. Simultaneous recordings from identified hippocampal complex spike cells at the highest dose of drug indicated that the DMTS deficit was associated with a specific decrease in hippocampal cell discharge during the Sample (but not the Match) phase of the task. In nine identified neurons (including four observed during both control and drug conditions) recorded from six different animals in which the effects of delta-9-THC were manifested, no indication of Sample phase firing was observed. Although there were slight but significant reductions in Match and Reinforcement phase related firing during THC sessions, highly significant increases in firing in these phases were still present, indicating that elimination of Sample phase firing did not reflect a nonspecific effect of delta-9-THC on hippocampal cell activity. These findings strongly suggest that performance of the DMTS task was selectively impaired by the lack of Sample phase discharge of hippocampal neurons during the DMTS trial, and that this effect could serve as the basis for the well characterized short-term memory and other cognitive deficits reported in humans after smoking marijuana.
Comparable studies
Other preclinical and animal studies on cannabis, most cited first.
Citations in the library
Cited by 30
- Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects ofδ-9-THC Psychological Medicine March 5, 2018
- Cannabis smoke and oral Δ9THC enhance working memory in aged but not young adult subjects bioRxiv (Cold Spring Harbor Laboratory) September 29, 2024
- Effects of cannabis smoke and oral Δ9THC on cognition in young adult and aged rats Psychopharmacology February 7, 2025
- Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. British Journal of Pharmacology May 2019
- Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacology January 2018
and 25 more in the library